Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies to Present at the 35th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 55th Annual Meeting of the American College of Neuropsychopharmacology
NEW YORK, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced two ITI-007 poster presentations at the 55th Annual Meeting of
View HTML
Toggle Summary Intra-Cellular Therapies to Participate at Upcoming Investor Conferences
NEW YORK, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced it will participate at the following investor conferences in November 2016:
View HTML
Toggle Summary Intra-Cellular Therapies Reports Third Quarter 2016 Financial Results and Provides Corporate Update
NEW YORK, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended September 30, 2016, and provided a
View HTML
Toggle Summary Intra-Cellular Therapies to Host Third Quarter 2016 Financial Results Conference Call and Webcast
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program in Schizophrenia at the CNS Summit 2016 Annual Conference
NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today announced presentation (in oral and poster forms) of results from its clinical development program in schizophrenia that has replicated the efficacy of ITI-007 60 mg in two studies and found it to be safe
View HTML
Toggle Summary Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study ‘302)
Intra-Cellular Therapies to Host a Conference Call Today at 4:45 p.m. ET to Discuss Results
View HTML
Toggle Summary Intra-Cellular Therapies Reports Second Quarter 2016 Financial Results and Provides Corporate Update
NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the quarter ended June 30, 2016, and provided a
View HTML
Toggle Summary Intra-Cellular Therapies to Host Second Quarter 2016 Financial Results Conference Call and Webcast
NEW YORK, July 25, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies Reports Completion of Enrollment of ITI-007-302 Phase 3 Clinical Trial for the Treatment of Schizophrenia
NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced completion of enrollment in the second Phase 3 clinical trial
View HTML
Toggle Summary Intra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical Trial for the Treatment of Agitation in Patients with Dementia, Including Alzheimer's Disease
NEW YORK, June 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that, following communication with the U.S.
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the JMP Securities Life Sciences Conference View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Jefferies 2016 Healthcare Conference
NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2016 Annual Meeting
NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that data related to ITI-007, the Company's lead product candidate, will be
View HTML